Abstract
90K/Mac-2BP glycoprotein is involved in the immune defense against a variety of neoplasms and viral infections, modulating the activity of several effectors such as natural killer cells. Quite interestingly, 90K/Mac-2BP is associated to a poor response to interferon (IFN) alpha in hepatitis C virus (HCV) infected patients. Here, in 70 consecutive HCV chronic patients, we have evaluated 90K basal levels as a response predictor to combined therapy with Peginterferon and Ribavirin. We have found higher 90K levels in genotype 1/4 than in genotype 2/3 (p = 0.006) and in 62.5% of non-responders than in 20% of responders (p < 0.001). Genotype 1/4, higher 90K and gamma glutamyl transferase (gammaGT) levels resulted independently associated to a status of refractoriness to therapy. Consequently, evaluation of 90K serum levels seems to be a promising useful marker of response to combined therapy in HCV disease.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antigens, Neoplasm / biosynthesis
-
Antigens, Neoplasm / blood*
-
Biomarkers / blood
-
Drug Therapy, Combination
-
Female
-
Follow-Up Studies
-
Hepacivirus / drug effects
-
Hepacivirus / immunology*
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / immunology*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage*
-
Interferon-alpha / therapeutic use
-
Male
-
Membrane Glycoproteins / biosynthesis
-
Membrane Glycoproteins / blood*
-
Middle Aged
-
Polyethylene Glycols / administration & dosage*
-
Polyethylene Glycols / therapeutic use
-
Predictive Value of Tests
-
Recombinant Proteins
-
Ribavirin / administration & dosage*
-
Ribavirin / therapeutic use
Substances
-
Antigens, Neoplasm
-
Biomarkers
-
Interferon alpha-2
-
Interferon-alpha
-
Membrane Glycoproteins
-
Recombinant Proteins
-
TAA90K protein, human
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2a